

Market Data

ASP Isotopes Inc. Nasdaq: ASPI

Industry	Basic Materials
Price	\$3.34
52-Wk Range	\$0.28-\$4.97
Market Cap	\$163.4M
Shares Out.	48.9M
Float	23.4M
Insider Own.	50.2%
Institutional Own.	2.6%
Avg. Vol. (90-day)	544,621
Cash (mrq)	\$7.9M
LT Debt (mrq)	\$0M

Price data as of April 24, 2024

Auditor: EISNERAMPER LLP

Legal Counsel: Blank Rome LLP


Transfer Agent: Equiniti Trust Company, LLC

aspisotopes.com

Company Overview

ASP Isotopes is an isotope enrichment company utilizing technology developed in South Africa over the past 20 years to enrich isotopes of elements or molecules with low atomic masses. Many of these elements are unsuitable for enrichment using traditional methods such as centrifuges. The Company's initial focus is on producing and commercializing highly enriched isotopes for the healthcare and technology industries.

Development Pipeline



Value Proposition

ASP lsotopes harnesses two decades of research and development to produce a broad range of isotopes, serving the expanding needs of nuclear medicine and green nuclear energy sectors. The Company's cutting-edge technology positions it to meet critical global demands heightened by recent geopolitical dynamics.

With cold commissioning completed at its first plant and several strategic off-take agreements in place, ASP Isotopes is on track to become a leader in non-nuclear isotope supply by 2028. Noteworthy agreements include a \$27 million annual contract with BRICEM for Molybdenum-100, a \$3.8 million annual deal for Carbon-14 with a Canadian firm, and a significant \$9 million agreement with a U.S. customer, with initial deliveries expected in Q1 2024.

Financially, the Company is well-positioned with a robust balance sheet, highlighted by no long-term debt and significant cash reserves. Despite early-stage losses, ASP lsotopes is poised for substantial revenue growth, with expectations of impactful revenue starting in the first half of 2024 as it ramps up commercial production.

HC Wainwright recently reaffirmed its buy rating on ASP Isotopes, raising the price target to \$5.50 based on the Company's advanced de-risking measures and promising revenue prospects. This robust outlook, combined with strategic expansions and innovative operational strategies, underscores ASP Isotopes' strong potential for sustained growth and value creation for its shareholders.


RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip formations, company profiles, or other investor relations and presentations are subject to change. RedChip Companies and its affiliates may buy and self shares of securities or options of the issuers mentioned on this website at any time. The information contained herein is not a regresentation or warranty and is not an offer or solicitation of an offer to buy or sell any security. To the fullest event of the law, RedChip Companies, inc., our specialists, advisors, and partners will not be liable to any person or entity for the quality, accuracy, completeness, reliability or timeliness of the information provided, or for any direct, indirect, completeness of this information, Stock market huesting is inherently risky. RedChip Companies is not a responsible for any gains or asses that may result from any inaccuracy or incompleteness of this information. For toos in privided to any person or entity (including but not limited to lost profits, loss of opportunities, trading losses and damages that may result from any inaccuracy or incompleteness of this information. For more information on stock market investing is inherently risky. RedChip Companies in the responsible for any gains or losses that result from any inaccuracy or incompleteness of this information. For more information on stock market investing, visit the Securities and Exchange Commission ("SEC") at www.osc.gov.on.ca. ASP and anges and securities and Exchange Commission ("SEC") at www.osc.gov.on.ca. ASP and anges and securities. Investor relations materials or presentations that investor awareness service



Nasdaq: ASPI



Rapidly Advancing Operations



Investment Highlights

Signed 25-year supply agreement valued at up to \$27 million per annum

 Agreement for highly enriched Molybdenum-100 (Mo-100) with BRICEM (Beijing Research Institute of Chemical Engineering Metallurgy)

Signed multi-year supply agreement targeting \$3.8 million revenue per annum

- Agreement for highly enriched Carbon-14 (C-14) with RC-14, a Canadian company
- Initial contract term is two years and can be extended to 10 years

Signed \$9 million supply contract with US customer

Received first prepayment in Q3 2023 of approximately \$900,000; commercial supply of enriched isotope projected for Q1 2024

Signed two MOUs with small modular reactor companies to supply High Assay Low Enriched Uranium (HALEU)

- Created new subsidiary, Quantum Leap Energy LLC, to supply commercial quantities of HALEU
- \$30 billion of HALEU demand expected based on initial discussions with customers

ASP technology is a low capital cost and environmentally friendly method of isotope production

- Enrichment facilities using ASP tech can be constructed at a fraction of cost and time vs traditional facilities with small footprint plants and modular design enabling capacity expansion
- ASP technology harvests and enriches a natural mix of isotopes without need for nuclear reactor by-products; ASP plant produces zero waste (not radioactive nor any other waste in any form)

Geo-political uncertainty and plant phase-outs create significant opportunity

- Planned phase-out of 9 of 10 old research nuclear reactors over next decade creates large shortfall in the global supply for Mo-99 and other isotopes
- Russia and China previously key global suppliers of isotopes; recent geopolitical events have forced governments and other customers to reassess their reliance on these suppliers

Highly experienced leadership team

- Paul Mann, Co-Founder, Chairman, CEO, CFO; 20+ years' experience on Wall Street investing in healthcare and chemicals companies, having worked at Soros Fund Management, Highbridge Capital Management and Morgan Stanley; began career as a research scientist at Proctor & Gamble
- Hendrik Strydom, PhD, Director, CTO; 30+ years' experience in isotope enrichment; co-developed isotope separation technology that is backbone of ASP Isotopes

Buy rating & \$5.50 per share price target from HC Wainwright (coverage initiated in December 2023; PT updated in April 2024)

RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and self shares of securities or options of the issuers mentioned on this website at any time. The information contained herein is not a representation or warranty and is not an offer or solicitation of an offer to buy or sell any security. To the fullest extent of the law, RedChip Companies, Inc., our specialists, advisors, and partners will not be liable to any person or entity for the quality, accuracy, completeness, reliability or timeliness of the information provided, or for any direct, indirect, consequential, incidental, special or punities to long partners will not be liable to any person or entity findual gubt not limited to lost profiles, loss of opportunities, trading losses and damages that may result from any inaccuracy or in completeness of this information. Stock market investing is inherently risky. RedChip Companies is not responsible for any gains or losses that result from the opinions expressed on this website at Exchange Commission ("SEC") at www.sec.gov. and/or the Datio Sec. Market investing, single and Exchange Commission ("SEC") at www.sec.gov. and/or the Ontario Securities. As Securities and Exchange Commission ("SEC") at www.sec.gov. and/or the Ontario Services. Investor awareness services. Investor awareness services and programs are easing to help small-cap companies is on the investor awareness services. Investor awareness services and programs are easing to help small-cap companies on t